ST-1891 for Hypothyroidism

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Sention Investigational Site, Chesterfield, MO
Hypothyroidism
ST-1891 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

ST-1891-201 is a multicenter, randomized, double-blind, crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hypothyroidism

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Week 26

Week 26
Percent of patients with thyroid-stimulating hormone levels within the standard reference range
The ratio of the levothyroxine daily dose at Screening to the ST-1891 daily dose at Week 26 for patients with thyroid-stimulating hormone levels within the standard reference range per central laboratory testing at Week 26

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Hypothyroidism

Trial Design

2 Treatment Groups

Levothyroxine
1 of 2
ST-1891
1 of 2
Active Control
Experimental Treatment

300 Total Participants · 2 Treatment Groups

Primary Treatment: ST-1891 · No Placebo Group · Phase 2

ST-1891
Drug
Experimental Group · 1 Intervention: ST-1891 · Intervention Types: Drug
Levothyroxine
Drug
ActiveComparator Group · 1 Intervention: Levothyroxine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 26
Closest Location: Sention Investigational Site · Chesterfield, MO
N/AFirst Recorded Clinical Trial
1 TrialsResearching Hypothyroidism
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have been taking levothyroxine for 3 months or more prior to Screening.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.